Ctla4 - cytotoxic T-lymphocyte-associated protein 4 Gene

Rattus norvegicus

Also known as Cd152; CTLA-4; sCTLA4

Gene ID: 63835 | Gene type: protein coding

About Ctla4

Primary_assembly 9: 62,319,312-62,324,963 forward strand.mRatBN7.2:CM026982.1

This gene has 2 transcripts (splice variants), 157 orthologues, 1 paralogue and is associated with 89 phenotypes. Biased expression in Thymus (RPKM 27.4), Spleen (RPKM 6.8) and 3 other tissues.

Summary

Predicted to enable signaling receptor activity. Involved in negative regulation of T cell proliferation and negative regulation of immune response. Predicted to be located in Golgi apparatus; clathrin-coated endocytic vesicle; and perinuclear region of cytoplasm. Predicted to be integral component of plasma membrane. Predicted to be part of protein complex involved in cell adhesion. Predicted to be active in external side of plasma membrane. Used to study myocarditis. Human ortholog(s) of this gene implicated in several diseases, including carcinoma (multiple); hematologic Cancer (multiple); hepatitis B; kidney disease (multiple); and primary immunodeficiency disease (multiple). Orthologous to human CTLA4 (cytotoxic T-lymphocyte associated protein 4). [provided by Alliance of Genome Resources, Apr 2022]

Ctla4 Products(1)

mRNA	Protein	Name
NM_031674.1	NP_113862.1	cytotoxic T-lymphocyte protein 4 precursor

Ctla4 Protein Structure

IgV_CTLA-4

0
100
200
223 a.a.

Protein Preferred Names

Protein Names

cytotoxic T-lymphocyte protein 4

CD152 antigen	soluble form
transmembrane form

Recombinant Ctla4 Proteins

Cat. No.	Product Name	Accession	Purity
HY-P74215	CTLA-4 Protein, Rat (HEK293, His)	Q62859 (E36-D161)	≥95%
HY-P74216	CTLA-4 Protein, Rat (HEK293, Fc)	Q62859 (M1-D161)	≥95%

Related Agents

Approval

Inhibitory Antibodies (3)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-P9901	Ipilimumab	Inhibitor	99.88%	Unkown
HY-108829	Abatacept		≥99.0%	Unkown
HY-P9918	Tremelimumab		99.50%	Unkown

Clinical Phase

Inhibitory Antibodies (10)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P99117	Cadonilimab		99.29%	Phase 3
HY-P99484	Botensilimab	Inhibitor	97.18%	Phase 3
HY-P990042	Gotistobart	Inhibitor	98.00%	Phase 3
HY-P99540	Tuvonralimab	Inhibitor	99.14%	Phase 3
HY-P99166	Vudalimab	Inhibitor	99.90%	Phase 2
HY-P99514	Zalifrelimab	Inhibitor	/	Phase 2
HY-P99809	Quavonlimab	Inhibitor	≥99.0%	Phase 2
HY-P99714	Lorigerlimab	Inhibitor	/	Phase 2
HY-P99844	Davoceticept		/	Phase 1
HY-P99760	Nurulimab	Inhibitor	95.00%	Phase 1

Pre-clinical Phase

Bioactive Molecules (3)

Cat. No.	Product Name	Purity	Rare Diseases
HY-RS03299	CTLA4 Human Pre-designed siRNA Set A	/	Unkown
HY-RS03300	Ctla4 Mouse Pre-designed siRNA Set A	/	Unkown
HY-RS03301	Ctla4 Rat Pre-designed siRNA Set A	/	Unkown

Inhibitory Antibodies (6)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-P99132	Anti-Mouse CTLA-4 Antibody (9D9)		≥98.0%	Unkown
HY-P990041	Firastotug	Inhibitor	/	Unkown
HY-P990048	Muzastotug	Inhibitor	/	Unkown
HY-P99354	Bavunalimab		/	Unkown
HY-P990080	Sovipostobart	Inhibitor	/	Unkown
HY-108829A	Abatacept (powder)	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Ctla4	NCBI	NCBI:1493
Canis familiaris	Ctla4	NCBI	NCBI:403696
Macaca fascicularis	Ctla4	NCBI	NCBI:102115124
Mus musculus	Ctla4	NCBI	NCBI:12477
Macaca mulatta	Ctla4	NCBI	NCBI:705673

Name
Email *

	Sorry, but the email address you supplied was invalid.